The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Anticipated For The Stomach Cancer Market Over The Period 2026–2030?
The market size for stomach cancer has seen considerable expansion in recent times. It is projected to expand from $3.74 billion in 2025 to $4.26 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.9%. This historical progression can be attributed to several factors: an escalating global incidence of gastric cancer, the widespread occurrence of Helicobacter pylori infections, the growing application of chemotherapy as a standard treatment, the development of hospital oncology infrastructure, and enhancements in diagnostic imaging techniques.
The stomach cancer market is anticipated to experience substantial growth in the upcoming years, with its value projected to reach $7.14 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.8%. This expansion during the forecast period is primarily driven by the increasing integration of precision oncology, a surge in investments in novel biologics, the development of more extensive immunotherapy pipelines, a heightened focus on detecting cancer at early stages, and improved accessibility to advanced cancer treatments. Prominent trends for the forecast period include the expanding application of targeted therapy regimens, a rise in the utilization of immunotherapy combinations, a greater emphasis on early diagnostic screenings, the broadening of personalized treatment approaches, and enhanced incorporation of biomarker-based testing.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25913&type=smp
Which Major Factors Are Driving The Expansion Of The Stomach Cancer Market?
An anticipated increase in the stomach cancer market’s growth is linked to the growing occurrence of Helicobacter pylori infection. This infection is a condition resulting from the Helicobacter pylori bacteria, which inhabits the stomach lining and can potentially result in inflammation, ulcers, and a heightened risk of stomach cancer. The increasing spread of Helicobacter pylori infection largely stems from inadequate sanitation, aiding the bacteria’s fecal-oral and oral-oral transmission in densely populated or unsanitary environments. Helicobacter pylori infection contributes to stomach cancer progression through inducing persistent inflammation and cellular harm to the stomach lining, ultimately fostering precancerous transformations and tumor formation. As an illustration, the Government of Canada, a government agency based in Canada, reported in November 2024 that the recurrence rate for Helicobacter pylori infection stood at 19% in 2023, with variations observed according to geographical location and age group. Consequently, the expanding occurrence of Helicobacter pylori infection is a key factor propelling the expansion of the stomach cancer market.
How Is The Stomach Cancer Market Divided Into Its Major Segments?
The stomach cancer market covered in this report is segmented –
1) By Type: Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Types
2) By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery
3) By Route Of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users
Subsegments:
1) By Adenocarcinoma: Intestinal Type, Diffuse Type
2) By Lymphoma: Mucosa-Associated Lymphoid Tissue Lymphoma, Diffuse Large B-Cell Lymphoma
3) By Gastrointestinal Stromal Tumor: Kit-Positive Gastrointestinal Stromal Tumor, Platelet-Derived Growth Factor Receptor Alpha-mutant Gastrointestinal Stromal, Wild-Type Gastrointestinal Stromal Tumors
4) By Carcinoid Tumor: Typical Carcinoid, Atypical Carcinoid
5) By Other Types: Squamous Cell Carcinoma, Small Cell Carcinoma, Undifferentiated Tumors
What Key Trends Are Influencing The Development Of The Stomach Cancer Market?
Leading companies in the stomach cancer treatment market are concentrating on developing advanced solutions, such as claudin (CLDN18.2)-targeted cytolytic antibody therapy, to improve precision in first-line treatments for HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinoma. Claudin (CLDN18.2)-targeted cytolytic antibody therapy involves a monoclonal antibody designed to selectively bind to CLDN18.2-expressing tumor cells and induce cytotoxic effects when combined with chemotherapy, thereby enhancing both progression-free and overall survival outcomes. For instance, in October 2024, Astellas Pharma US, Inc., a Japan-based pharmaceutical company, launched Vyloy (zolbetuximab-clzb), a claudin (CLDN18.2)-directed cytolytic antibody for gastric and gastroesophageal junction (GEJ) cancer treatment. This innovative biologic therapy is administered intravenously alongside fluoropyrimidine- and platinum-containing chemotherapy, having shown a median progression-free survival benefit of up to 10.6 months and overall survival of up to 18.2 months in clinical trials. This therapy selectively targets CLDN18.2-positive cancer cells, leading to reduced off-target toxicity and increased treatment specificity, which signifies a substantial advancement in personalized oncology for advanced gastric cancer.
Who Are The Prominent Organizations Shaping The Stomach Cancer Market?
Major companies operating in the stomach cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck And Co. Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Amgen Inc, Daiichi Sankyo Company Limited, BeiGene Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited, Zai Lab Limited, MacroGenics Inc., Astellas Pharma Inc., Ipsen Group, AbbVie Inc., Bayer AG, Ono Pharmaceutical Co. Ltd.
Read the full stomach cancer market report here:
https://www.thebusinessresearchcompany.com/report/stomach-cancer-global-market-report
Which Region Currently Holds The Largest Share Of The Stomach Cancer Market?
North America was the largest region in the stomach cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stomach cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Stomach Cancer Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25913&type=smp
Browse Through More Reports Similar to the Global Stomach Cancer Market 2026, By The Business Research Company
Esophageal Cancer Global Market Report
https://www.thebusinessresearchcompany.com/report/esophageal-cancer-global-market-report
Gastric Cancer Diagnostic Procedure Global Market Report
Tumor Ablation Global Market Report
https://www.thebusinessresearchcompany.com/report/tumor-ablation-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model